19-0021 Clinical Study
C. diff Clinical Trials

A Randomized, Double-Blind Evaluation of CRS3123 Versus Oral Vancomycin in Adult Patients with Clostridioides difficile Infection.

About CRS3123

CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies.

  • Highly potent against all clinical isolates of C. difficile
  • Narrow spectrum for C. difficile, which may substantially reduce the disruption of normal intestinal microbiota compared to current therapies
  • Inhibition of toxin production, potentially leading to lower morbidity and mortality, and faster resolution of symptoms
  • Inhibition of sporulation, potentially leading to lower rates of transmission and recurrence
  • Novel mechanism of action, which means that its use will not compromise the utility of systemic antibiotics (e.g. vancomycin)

Watch the video above to learn more about CRS3123 and our phase 2 clinical trial.

Studies & Publications

Crestone team attending a presentation

Safety, Tolerability, Systemic Exposure, and Metabolism of CRS3123

This first-in-human, double-blind, placebo-controlled, dose escalation study evaluated the safety and systemic exposure of CRS3123 after a single oral dose in healthy adults. View publication & study results

Crestone team members working on a C. difficile study in the lab.

Multiple-Ascending-Dose Phase 1 Clinical Study of CRS3123

CRS3123 has been evaluated in a multiple-ascending-dose placebo-controlled phase 1 trial with thirty healthy participants to determine the safety, tolerability, and pharmacokinetics of CRS3123. View publication & study results

News & Press Releases

Crestone team members in a meeting

Crestone, Inc. Secures NIH Funding for Phase 2 Clinical Trial

September 12, 2019: Crestone, Inc., today announced a Contract Award from the NIH focused on the Phase 2 clinical development of its small molecule drug candidate, CRS3123. View full press release

A few of the Crestone team members ready to analyze C. diff trials in the lab.

Crestone, Inc. Enrolls First Patient in Phase 2 Clinical Trial for Novel Antibiotic CRS3123

June 07, 2021: Crestone, Inc. announced the first patient has been enrolled in a Phase 2 clinical trial of CRS3123. Additionally, the FDA has granted Qualified Infectious Disease Product designation and Fast Track designation for the treatment of CDI. View full press release

About Crestone, Inc.

Boulder, Colorado-based Crestone, Inc. is a clinical stage biopharmaceutical company focused on inventing and developing novel mechanism of action small molecule drugs for serious bacterial infections. Its pipeline includes antibacterial agents to treat CDI, resistant Gram-positive infections such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), and chronic infections such as nontuberculous mycobacterial (NTM) disease.

Learn More About Crestone, Inc.